Afferent Pharmaceuticals Names Kathleen Sereda Glaub as Chief Executive Officer
September 10, 2014Afferent Pharmaceuticals announced that Kathleen Sereda Glaub, who has been serving as a member of Afferent's Board since 2013, has been named Chief Executive Officer.
More »
Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 9, 2014Durata announced data from its recent product, DALVANCE™ (dalbavancin) for injection, was presented during the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which took place in Washington DC September 5-9, 2014.
More »
Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
September 9, 2014Evoke Pharma has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead product candidate. The study is fully enrolled with 48 patients, ahead of the Company's original projected timeframe.
More »